While Aardvark Therapeutics is interested in serving this market, first it wants to validate its approach by treating patients whose excessive eating is rooted in a rare genetic disorder.

GREEN BAY − After seven years, a popular downtown winery and lounge will close this month. Aardvark Wine Lounge, 304 Pine St., in Green Bay opened Jan. 6, 2017 and will officially close on Feb ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Obesity drug developer Aardvark Therapeutics (NASDAQ:AARD) has filed for a $100M initial public offering. Aardvark (NASDAQ:AARD) didn't disclose any terms in its SEC filing, but indicated in its ...

Aardvark may be close behind with a medicine codenamed ARD-101. The company’s drug acts on certain types of so-called bitter taste receptors which, as their name suggests, convey acrid flavor from the ...

Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on the Nasdaq early Thursday. The company had initially filed plans for its IPO ...

Welcome to the new I Found the Aardvark points page! On this page you will be able to log your aardvark finds and gain points which can then be spent on great aardvark gear! Total Number of Hunters: ...

Our regular round-up of financings in the biotech sector is headed by rumours of a $150 to $200 million initial public offering (IPO) for Aardvark Therapeutics, an emerging player in the weight ...

In a 2025 punctuated by news from the weight-loss space, obesity-focused biotech Aardvark Therapeutics filed for an IPO Thursday, following competitor Metsera, which announced its own bid earlier this ...

Obesity-focused Aardvark Therapeutics is hoping to raise $100 million in an initial public offering (IPO), according to a US Securities and Exchange Commission (SEC) filing. The Californian biopharma ...